Preclinical Toolbox

Looking to advance your research? Use our optimised compounds to explore and validate mechanisms and pathways in disease-related models of interest to you.


We offer compounds with optimised pharmacological properties for preclinical research that will advance scientific knowledge by exploring novel disease biology. 

Types of preclinical studies considered:

  • In vitro studies that support understanding of disease biology using cells and/or ex vivo tissues from humans or animals
  • In vivo animal studies in models that have translatable endpoints to human disease and could be used to support progression to clinical studies
  • Compound/mechanism combination studies to uncover synergies between pathways leading to novel disease insight and potential therapies.

Let's partner in preclinical research

We invite disease expert physicians and basic scientists to partner with us, with each other and with public or private funding bodies to brainstorm, design and execute preclinical translational research. The aim is to generate high quality, novel data to support the future discovery and development of new therapeutics through target validation, efficacy in models of disease and mechanistic insight into the pathophysiology of human disease.

Interested investigators are invited to:

  • Explore our sortable Preclinical Table of Compounds and examine the key properties of any  compound/mechanism of interest
  • Learn the process, criteria, and rough timelines for proposal submission through to full project plan development and final approval
  • Submit a short 2-3 page ‘Concept Proposal’.

Additional marketed, biologic and late-stage clinical development compounds are offered via the AstraZeneca Externally Sponsored Scientific Research portal.

Submitting a preclinical research proposal



Preclinical compounds available

Filter By

Display
Compound Mechanism of action Originating therapeutic area Proposal type CNS Penetrant Target class Original indication Route
AZ11657312 Mechanism of action Purinergic receptor 2X, ligand-gated ion channel 7 (P2X7) antagonist Originating therapeutic area Inflammation Proposal type Preclinical CNS Penetrant Low Target class Ligand-gated ion channel Original indication COPD, Crohn's, OA, RA Route Oral
AZ12861903 Mechanism of action Growth hormone secretagogue receptor type 1a (GHS-R1a) inverse agonist; ghrelin receptor inverse agonist Originating therapeutic area Metabolic Disease Proposal type Preclinical CNS Penetrant Yes Target class GPCR Original indication Obesity Route Oral
AZ12971554 Mechanism of action Thrombin inhibitor Originating therapeutic area Cardiovascular Proposal type Preclinical CNS Penetrant Unknown Target class Enzyme Original indication Thromboembolism prevention Route Oral
AZ12977847 Mechanism of action Negative allosteric modulator of human mGluR5d, human mGluR5b Originating therapeutic area GI Proposal type Preclinical CNS Penetrant Low Target class GPCR Original indication gastro-oesophageal reflux disease Route Oral
AZ13483342 Mechanism of action Melanin concentrating hormone receptor 1 (MCH1) antagonist  Originating therapeutic area Metabolic Disease Proposal type Preclinical CNS Penetrant Yes Target class GPCR Original indication Obesity Route Oral
AZ20 Mechanism of action ATR serine/threonine kinase inhibitor Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Oncology Route Oral
AZ32 Mechanism of action ATM kinase inhibitor Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Yes Target class Kinase Original indication ATM kinase inhibitor (for preclinical use to radiosensitise tumour cells in vitro and in vivo) Route Oral
AZ6102 Mechanism of action Tankyrase 1 and 2 inhibitor (TNKS1/2) inhibitor    Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Enzyme Original indication various tumor types Route IV
AZD0328 Mechanism of action Nicotinic acetylcholine receptor alpha 7 (α7 nAChR) agonist Originating therapeutic area CNS Proposal type Clinical & Preclinical CNS Penetrant Yes Target class Ligand-gated ion channel Original indication Cognitive impairment Route Oral
AZD1236 Mechanism of action Matrix metalloproteinase 9 & 12 (MMP9,12) inhibitor Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target class Enzyme Original indication COPD Route Oral
AZD1390 Mechanism of action Brain penetrant Ataxia telangiectasia mutant (ATM) kinase inhibitor Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Yes Target class Kinase Original indication Glioblastoma and brain metastases Route Oral
AZD1656 Mechanism of action Glucokinase (GK; hexokinase 4) activator Originating therapeutic area Metabolic Disease Proposal type Clinical & Preclinical CNS Penetrant Low Target class Enzyme Original indication Diabetes Route Oral
AZD1775 Mechanism of action WEE1 G2 checkpoint kinase inhibitor  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Unknown Target class Kinase Original indication Advanced Solid Tumours Route Oral
AZD1981 Mechanism of action Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist [prostaglandin D2 (DP2) receptor antagonist] Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target class GPCR Original indication Asthma, COPD Route Oral
AZD2906 Mechanism of action Glucocorticoid receptor (GR) full agonist Originating therapeutic area Inflammation Proposal type Preclinical CNS Penetrant Unknown Target class Nuclear Hormone Receptor Original indication Rheumatoid arthritis Route Oral
AZD2927 Mechanism of action Acetylcholine-regulated inwardly rectifying potassium current (IKACh) blocker  Originating therapeutic area Cardiovascular Proposal type Preclinical CNS Penetrant Low Target class Ligand-gated ion channel Original indication Atrial fibrillation Route IV
AZD3458 Mechanism of action Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PI3Kɣ) inhibitor Originating therapeutic area Inflammation Proposal type Preclinical CNS Penetrant Low Target class Kinase Original indication Inflammation Route Oral
AZD3839 Mechanism of action AZD3839 is a brain-permeable oral inhibitor of human beta-site amyloid (Aβ) precursor protein-cleaving enzyme1 (BACE1) Originating therapeutic area CNS Proposal type Preclinical CNS Penetrant Yes Target class CNS Original indication Alzheimers disease Route Oral
AZD3857 Mechanism of action Melanin concentrating hormone receptor 1 (MCH1) antagonist and acetylcholinesterase (AChE) inhibitor    Originating therapeutic area Metabolic Disease Proposal type Preclinical CNS Penetrant Yes Target class GPCR Original indication Obesity Route Oral
AZD4017 Mechanism of action 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor Originating therapeutic area Metabolic Disease Proposal type Clinical & Preclinical CNS Penetrant Low Target class Enzyme Original indication Diabetes Route Oral
AZD4320 Mechanism of action BH3 mimetic inhibitor of the anti-apoptotic protein BCL-2 and BCL-xL Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Hematological malignancies (AML, MDS, NHL, MM, CLL, SCL, TCL, RS) Route IV
AZD4547 Mechanism of action Fibroblast growth factor receptor (FGFR) tyrosine kinase family inhibitor      Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Low Target class Kinase Original indication Solid Tumours Route Oral
AZD4573 Mechanism of action Cyclin dependent kinase 9 (CDK9) Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Hematological malignancies (AML, MDS, NHL, MM, CLL, SCL, TCL, RS) Route IV
AZD5069 Mechanism of action Chemokine (C-X-C motif) receptor 2 (CXCR2) antagonist Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Unknown Target class GPCR Original indication Asthma Route Oral
AZD5213 Mechanism of action Histamine receptor 3 (H3) antagonist (inverse agonist) Originating therapeutic area CNS Proposal type Clinical & Preclinical CNS Penetrant Yes Target class GPCR Original indication Cognition, Daytime Sleepiness, Tourette's Route Oral
AZD5363 Mechanism of action AKT serine/threonine protein kinase (also known as protein kinase B alpha) inhibitor  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Low Target class Kinase Original indication Solid & Haematological Malignancies Route Oral
AZD5634 Mechanism of action ENaC Inhibitor Originating therapeutic area Respiratory & Immunology Proposal type Preclinical/ Clinical CNS Penetrant Unknown Target class Sodium Channel Original indication Route
AZD5904 Mechanism of action Myeloperoxidase (MPO) inhibitor Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target class Enzyme Original indication COPD, MS Route Oral
AZD5991 Mechanism of action BH3 mimetic inhibitor of the anti-apoptotic protein Mcl-1 Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Hematological malignancies (AML, MDS, NHL, MM, CLL, SCL, TCL, RS) Route IV
AZD6703 Mechanism of action P38 alpha Inhibitor Originating therapeutic area Inflammation Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Inhibitor Original indication Inflammation Route Oral
AZD6738 Mechanism of action Ataxia Telangiectasia and Rad3 related (ATR) serine/threonine protein kinase inhibitor  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Kinase Original indication Chronic Lymphocytic Leukaemia (CLL) Route Oral
AZD7624 Mechanism of action P38 alpha inhibitor Originating therapeutic area Inflammation Proposal type Preclinical CNS Penetrant Unknown Target class Kinase inhibitor Original indication COPD Route Inhaled
AZD8055 Mechanism of action Mammalian target of rapamycin (mTOR) kinase (TORC1/2) inhibitor Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant No Target class mTOR inhibitor Original indication Route Inhaled
AZD8329 Mechanism of action 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor Originating therapeutic area CVMD Proposal type Preclinical CNS Penetrant Low Target class Enzyme Original indication Diabetes Route Oral
AZD8529 Mechanism of action Metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator Originating therapeutic area CNS Proposal type Preclinical CNS Penetrant Yes Target class GPCR Original indication Schizophrenia Route Oral
AZD8701 Mechanism of action Forkhead-box P3 Transcription Factor Anti-Sense Oligonucleotide Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Unknown Target class Original indication Route
AZD9567 Mechanism of action Non-steroidal, selective glucocorticoid receptor modulator (oSGRM) Originating therapeutic area Inflammation Proposal type Preclinical CNS Penetrant Yes Target class Nuclear Horomone Receptor Original indication Inflammation Route Oral
Barasertib (AZD1152) Mechanism of action Aurora B serine/threonine kinase inhibitor  Originating therapeutic area Oncology Proposal type Preclinical CNS Penetrant Low Target class Kinase Original indication Acute Myeloid Leukaemia (AML) Route IV
Lesogaberan (AZD3355) Mechanism of action Gamma-aminobutyric acid receptor B (GABAB) agonist   Originating therapeutic area GI Proposal type Clinical & Preclinical CNS Penetrant Low Target class GPCR Original indication GERD Route Oral
Zibotentan (ZD4054) Mechanism of action Endothelin receptor A (ETA) antagonist  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Low Target class GPCR Original indication Castration-Resistant Prostate Cancer (CRPC) Route Oral


Open Innovation external funding

AstraZeneca collaborates with various government funding bodies and academic institutions to provide funding opportunities for studies that use our compounds.

Institution-specific funding opportunities

National Health Innovation Centre (Singapore)

Taiwan’s National Research Program for Biopharmaceuticals (NRPB) (Taiwan)

University of Queensland (Australia)



Useful information

How do I know that the information I submit to AstraZeneca will remain confidential?

AstraZeneca is committed to the same ethical policy that is practiced during grant and manuscript peer-reviews.  That means we will not use or disclose the information submitted, unless approved in writing by the submitter; or the information becomes public, is separately received or independently developed.

What are the typical agreement terms?

The AstraZeneca Open Innovation programme seeks to utilise terms that facilitate participation, open collaborative brainstorming, problem solving and are consistent with well-established and tested academic-industry agreement structures (e.g., Lambert/miCRA templates in U.K. and NIH/NCATS CRA in U.S.), for example:

  • Pre-existing IP remains with the original owner
  • New IP follows ownership framework taking into account the contribution of each party and where possible using the well-established academic-industry templates
  • Publications are encouraged after allowing AstraZeneca to comment, patent(s) to be filed (if applicable), AstraZeneca confidential information protected
  • If the collaboration generates positive findings, AstraZeneca has option to negotiate a license to advance further towards patient benefit and commercialisation
  • For compounds ‘live’ in development, AstraZeneca minimally receives non-exclusive, royalty-free, fully paid license, with the right to sublicense without limitation, for all purposes for project IP

Ownership of project IP is based on multiple factors including regional/country standards, IP policies and the current development stage/status of the compound